NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, has entered a long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen, through which NovAliX and the MPI aim to make the vital process of translating scientific research and academic insights into real therapies more efficient.
 
Prof. Dr. Holger Stark, Managing Director at the MPI for Multidisciplinary Sciences, highlights the potential of this partnership to propel progress and transformative advancements in the field of drug discovery: “The endpoint of fundamental academic research is still considerably distant from the initial stages of drug discovery. Bridging these phases is substantially important; the MPI’s and NovAliX’s complementary expertise will be essential for fostering successful therapeutic development.”
 
This partnership will enable early-stage collaboration, fusing the potential of the MPI experts’ discoveries and NovAliX’s award-winning scientists, and streamlining the integration of academic insights into drug development.
 
Dr. Denis Zeyer, CEO of NovAliX, remarks: “It is more costly and more risky than ever before to identify and bring new medicines to market. The current model is unsustainable. Bringing academic research deeper into the process can only increase the odds of success for therapeutic opportunities.”

Related News